Loading...
Please wait, while we are loading the content...
Similar Documents
Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial
| Content Provider | Scilit |
|---|---|
| Author | Zelenetz, Andrew D. Barrientos, Jacqueline C. Brown, Jennifer R. Coiffier, Bertrand Delgado, Julio Egyed, Miklós Ghia, Paolo Illés, Árpád Jurczak, Wojciech Marlton, Paula Montillo, Marco Morschhauser, Franck Pristupa, Alexander S. Robak, Tadeusz Sharman, Jeff P. Simpson, David Smolej, Lukáš Tausch, Eugen Adewoye, Adeboye H. Dreiling, Lyndah K. Kim, Yeonhee Stilgenbauer, Stephan Hillmen, Peter |
| Copyright Year | 2017 |
| Description | Journal: The Lancet Oncology |
| Related Links | http://europepmc.org/articles/pmc5589180?pdf=render https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5589180/pdf http://www.thelancet.com/article/S1470204516306714/pdf |
| Ending Page | 311 |
| Page Count | 15 |
| Starting Page | 297 |
| ISSN | 14702045 |
| e-ISSN | 14745488 |
| DOI | 10.1016/s1470-2045%2816%2930671-4 |
| Journal | The Lancet Oncology |
| Issue Number | 3 |
| Volume Number | 18 |
| Language | English |
| Publisher | Elsevier BV |
| Publisher Date | 2017-03-01 |
| Access Restriction | Open |
| Subject Keyword | Journal: The Lancet Oncology General Medicine Patients with Relapsed Combination with Bendamustine Free Survival Randomly Assigned Progression Free Rituximab in Patients |
| Content Type | Text |
| Resource Type | Article |
| Subject | Oncology |